JSM 2012 Home

JSM 2012 Online Program

The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.

Online Program Home

Abstract Details

Activity Number: 522
Type: Contributed
Date/Time: Wednesday, August 1, 2012 : 10:30 AM to 12:20 PM
Sponsor: Biopharmaceutical Section
Abstract - #305940
Title: Escalation with Overdose Control Using Ordinal Toxicity Grades for Cancer Phase I Clinical Trials
Author(s): Galen Cook-Wiens*+ and Mourad Tighiouart and Andre Rogatko
Companies: Cedars Sinai Medical Center and Cedars Sinai Medical Center and Cedars Sinai Medical Center
Address: , , ,
Keywords: EWOC ; Ordinal toxicity grade ; Maximum tolerated dose ; cancer phase I trials ; proportional odds model ; coherence

Dose finding studies in early phase cancer clinical trials are sequential designs aimed at estimating a maximum tolerated dose (MTD) for further phase II studies of efficacy. The majority of the statistical designs that were proposed in the last two decades allocate future doses based on a binary outcome of dose limiting toxicity (DLT) of previously treated patients. Such designs may not be efficient in the sense that the dose recommended for the next patient is the same regardless whether the previously treated patient had no toxicity or had intermediate grade 2 toxicity. In this article, we extend a Bayesian adaptive phase I clinical trial design known as escalation with overdose control (EWOC) by introducing an intermediate grade 2 toxicity when assessing DLT. Under the proportional odds model assumption of dose-toxicity relationship, we prove that in the absence of DLT, the dose allocated to the next patient given that the previously treated patient had a maximum of grade 2 toxicity is lower than the dose given to the next patient had the previously treated patient exhibited a grade 0 or 1 toxicity at the most. Further, we prove that the coherence properties of EWOC are preserved. Simulation results show that the safety of the trial is not compromised and the efficiency of the estimate of the MTD is maintained relative to EWOC treating DLT as a binary outcome and that fewer patients are overdosed using this design when the true MTD is close to the minimum dose.

The address information is for the authors that have a + after their name.
Authors who are presenting talks have a * after their name.

Back to the full JSM 2012 program

2012 JSM Online Program Home

For information, contact jsm@amstat.org or phone (888) 231-3473.

If you have questions about the Continuing Education program, please contact the Education Department.